| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8213623 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 25 Pages |
Abstract
We demonstrated that Promitil is an attractive agent for chemoradiotherapy because it demonstrates a radiation-triggered release of active drug. We further demonstrated that Promitil is a well-tolerated and potent radiosensitizer at doses not achievable with free MMC. These results support clinical investigations using Promitil in chemoradiotherapy.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Xi PhD, Samuel B. BS, Kyle T. BS, Joseph M. MD, PhD, Tian MD, Patricia PhD, Alberto A. MD, PhD, Andrew Z. MD,